AslistedinthePhysiciansDeskReference(PDR)

IMMUNOCAL PDR2015
NUTRACEUTICAL
Glutathioneprecursor(Bondedcysteinesupplement)
PowderSachets


DESCRIPTIONandCLINICALPHARMACOLOGY
IMMUNOCALisaU.S.patentednaturalfoodproteinisolateintheFDA
categoryofGRAS(generallyrecognizedassafe)whichassiststhebodyin
maintainingoptimalconcentrationsofglutathione(GSH)bysupplyingthe
precursorsrequiredforintracellularglutathionesynthesis.Itisclinically
proventoraiseglutathionevalues.

Glutathioneisatripeptidemadeintracellularlyfromitsconstituentamino
acidsLglutamate,Lcysteineandglycine.Thesulfhydryl(thiol)group(SH)
ofcysteineisresponsibleforthebiologicalactivityofglutathione.
Provisionofthisaminoacidistheratelimitingfactoringlutathionesynthesisbythecellssincebioavailablecysteineis
relativelyrareinfoodstuffs.

Immunocalisabovinewheyproteinisolatespeciallypreparedsoastoprovidearichsourceofbioavailablecysteine.
Immunocalcanthusbeviewedasacysteinedeliverysystem.

The disulphide bond in cystine is pepsin and trypsin resistant but may be split by heat, low pH or mechanical stress
releasing free cysteine. When subject to heat or shearing forces (inherent in most extraction processes), the fragile
disulfidebondswithinthepeptidesarebrokenandthebioavailabilityofcysteineisgreatlydiminished.

Glutathioneisatightlyregulatedintracellularconstituentandislimitedinitsproductionbynegativefeedbackinhibition
ofitsownsynthesisthroughtheenzymegammaglutamylcysteinesynthetase,thusgreatlyminimizinganypossibilityof
overdosage.

Glutathionehasmultiplefunctions:
1. Itisthemajorendogenousantioxidantproducedbythecells,participatingdirectlyintheneutralizationoffree
radicalsandreactiveoxygencompounds,aswellasmaintainingexogenousantioxidantssuchasvitaminsCandE
intheirreduced(active)forms.
2. Throughdirectconjugation,itdetoxifiesmanyxenobiotics(foreigncompounds)andcarcinogens,bothorganic
andinorganic.
3. It is essential for the immune system to exert its full potential, e.g. (1) modulating antigen presentation to
lymphocytes,therebyinfluencingcytokineproductionandtypeofresponse(cellularorhumoral)thatdevelops,
(2) enhancing proliferation of lymphocytes thereby increasing magnitude of response, (3) enhancing killing
activityofcytotoxicTcellsandNKcells,and(4)regulatingapoptosis,therebymaintainingcontroloftheimmune
response.
4. ItplaysafundamentalroleinnumerousmetabolicandbiochemicalreactionssuchasDNAsynthesisandrepair,
proteinsynthesis,prostaglandinsynthesis,aminoacidtransportandenzymeactivation.Thus,mostsystemsin
the body can be affected by the state of the glutathione system, especially the immune system, the nervous
system,thegastrointestinalsystemandthelungs.
INDICATIONSANDUSAGE
IMMUNOCALisanaturalfoodsupplementandassuchislimitedfromstatingmedicalclaimsperse.Statementshave
not been evaluated by the FDA. As such, this product is thus not intended to diagnose, cure, prevent or treat any
disease.

Glutathione augmentation is a strategy developed to address states of glutathione deficiency, high oxidative stress,
immunedeficiency,andxenobioticoverloadinwhichglutathioneplaysapartinthedetoxificationofthexenobioticin
question. Glutathione deficiency states include, but are not limited to: HIV/AIDS, infectious hepatitis, certain types of
cancers,cataracts,AlzheimersDisease,Parkinsons,chronicobstructivepulmonarydisease,asthma,radiation,poisoning
byacetominophenandrelatedagents,malnutritivestates,arduousphysicalstress,aging,andhasbeenassociatedwith
suboptimalimmuneresponse.Manyclinicalpathologiesareassociatedwithoxidativestressandareelaboratedupon
innumerousmedicalreferences.

Low glutathione is also strongly implicated in wastingandnegativenitrogenbalance,notablyasseenincancer,AIDS,

sepsis,trauma,burnsandevenathleticovertraining.CysteinesupplementationcanopposethisprocessandinAIDS,for
example,resultinimprovedsurvivalrates.

CONTRAINDICATIONS
IMMUNOCALiscontraindicatedinindividualswhodeveloporhaveknownhypersensitivitytospecificmilkproteins.

PRECAUTIONS
EachsachetofIMMUNOCALcontainsninegramsofprotein.Patientsonaproteinrestricteddietneedtotakethisinto
accountwhencalculatingtheirdailyproteinload.Althoughabovinemilkderivative,IMMUNOCALcontainslessthan
1%lactoseandthereforeisgenerallywelltoleratedbylactoseintolerantindividuals.

WARNINGS
Patientsundergoingimmunosuppressivetherapyshoulddiscusstheuseofthisproductwiththeirhealthprofessional.
Individuals with the autosomalrecessive metabolic disorder cystinuria, are at higher risk of developing cysteine
nephrolithiasis(12%ofrenalcalculi).

ADVERSEREACTIONS
Gastrointestinal bloating and cramps if not sufficiently rehydrated. Transient urticariallike rash in rare individuals
undergoingseveredetoxificationreaction.Rashabateswhenproductintakestoppedorreduced.

OVERDOSAGE
OverdosingonIMMUNOCALhasnotbeenreported.

DOSAGEANDADMINISTRATION
Formildtomoderatehealthchallenges,20gramsperdayisrecommended.ClinicaltrialsinpatientswithAIDS,COPD,
cancer and chronic fatigue syndrome have used 3040 grams per day without ill effect. IMMUNOCAL is best
administeredonanemptystomachorwithalightmeal.Concomitantintakeofanotherhighproteinloadmayadversely
affectabsorption.

RECONSTITUTION
IMMUNOCAL is a dehydrated powdered protein isolate. It must be appropriately rehydrated before use. Ideally
consumed after mixing. If it is premixed for later consumption, it should be refrigerated and consumed shortly after
mixing.DONOTheatoruseahotliquidtorehydratetheproduct.DONOTuseahighspeedblenderforreconstitution.
Thesemethodswilldecreasetheactivityoftheproduct.

Propermixingisimperative.Consultinstructionsincludedinpackaging.
HOWSUPPLIED
10gramsofbovinemilkproteinisolatepowderpersachet.
30sachetsperbox.

STORAGE
Storeinacooldryenvironment.Refrigerationisnotnecessary.

REFERENCES
1. BaruchelS,ViauG,OlivierR.etal.Nutraceuticalmodulationofglutathionewithahumanizednativemilkserum
proteinisolate,Immunocal:applicationinAIDSandcancer.In:OxidativeStressinCancer,AIDSand
NeurodegenerativeDiseases.Ed.;MontagnierL,OlivierR,PasquierC.MarcelDekkerInc.NewYork,447461,1998
2. BounousG,KongshavnP.Influenceofproteintypeinnutritionallyadequatedietsonthedevelopmentofimmunity.
InAbsorptionandUtilizationofAminoAcidsVol.II.Ed.M.Friedman.CRCPress,Inc.,Fla.2:21932,1989
3. BounousG,GoldP.Thebiologicalactivityofundenaturedwheyproteins:roleofglutathione.ClinInvestMed
14:296309,1991
4. BounousG,BaruchelS,FalutzJ.GoldP.WheyproteinsasafoodsupplementinHIVseropositiveindividuals.Clin
InvestMed.16:3;204209,1992
5. BounousG.Wheyproteinconcentrate(WPC)andglutathionemodulationincancertreatment.AnticancerRes.
20:47854792,2000
6. BounousG.ImmunoenhancingpropertiesofundenaturedmilkserumproteinisolateinHIVpatients.Int.DiaryFed:
Whey:293305,1998
7. BrayT,TaylorC.Enhancementoftissueglutathioneforantioxidantandimmunefunctionsinmalnutrition.Biochem.
Pharmacol.47:21132123,1994.
8. DrogeW,HolmE.RoleofcysteineandglutathioneinHIVinfectionandotherdiseasesassociatedwithmuscle
wastingandimmunologicaldysfunction.FASEBJ:11(13):10771089,1997
9. HerzenbergLA,DeRosaSC,DubsJGetal.GlutathionedeficiencyisassociatedwithimpairedsurvivalinHIVdisease.
ProcNatlAcadSci94:196772,1997
10. KennedyR,KonokG,BounousGetal..Theuseofawheyproteinconcentrateinthetreatmentofpatientswith
metastaticcarcinoma:Aphase1IIclinicalstudy.AnticancerRes.15:264350,1995
11. LandsLC,GreyVL,SmountasAA.Effectofsupplementationwithacysteinedonoronmuscularperformance.J.Appl.
Physiol.87:13811385,1999
12. LocignoR,CastronovoV.ReducedglutathioneSystem:Roleincancerdevelopment,preventionandtreatment.
InternationalJournalofOncology19:221236,2001
13. LomaestroB,MaloneM.Glutathioneinhealthanddisease:pharmacotherapeuticissues.AnnPharmacother29:
126373,1995
14. LothianB,GreyV,KimoffRJ,Lands.Treatmentofobstructiveairwaydiseasewithacysteinedonorprotein
supplement:acasereport.Chest117:914916,2000
15. MeisterA.Glutathione.AnnRevBiochem52:71160,1983
16. PetersonJD,HerzenbergLA,VasquezKK,WaltenbaughC.Glutathionelevelsinantigenpresentingcellsmodulate
Th1versusTh2responsepatterns.Proc.Natl.Acad.Sci.95:30713076,1998
17. TozerRG,TaiP,FalconerW,DucruetT,KarabadjianA,BounousG,MolsonJ,DrgeW.Cysteinerichproteinreverses
weightlossinlungcancerpatientsreceivingchemotherapyorradiotherapy.Antioxidants&redoxsignaling.10:395
402,2008.
18. WatanabeA,HigachiK,YasumuraS.etal.Nutritionalmodulationofglutathionelevelandcellularimmunityin
chronichepatitisBandC.Hepatology.24:597A,1996
19. WitschiA,ReddyS,StoferB,LauterbergB.Thesystemicavailabilityoforalglutathione.Eur.J.Clin.Pharmacol.
43:667669,1992.